Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York.
Cell Mol Gastroenterol Hepatol. 2019;8(1):37-60. doi: 10.1016/j.jcmgh.2019.02.009. Epub 2019 Mar 2.
BACKGROUND & AIMS: Most targeted therapies against cancer are designed to block growth factor-stimulated oncogenic growth. However, response rates are low, and resistance to therapy is high. One mechanism might relate to the ability of tumor cells to induce growth factor-independent proliferation (GFIP). This project aims to understand how (1) cancer cells preferentially derive a major growth advantage by using critical metabolic products of glucose, such as phosphoenolpyruvate (PEP), to drive proliferation and (2) esophageal squamous cell carcinoma (ESCC) cells, but not esophageal adenocarcinoma cells, can induce GFIP by using glycolysis to activate phosphohistidine (poHis)-mediated signaling through focal adhesion kinase (FAK).
The hypothesis to be tested is that ESCC GFIP induced by glucose is facilitated by PEP-mediated histidine phosphorylation (poHis) of FAK, leading to the possibility that ESCC progression can be targeted by blocking poHis signaling. Biochemical, molecular biological, and in vivo experiments including bromodeoxyuridine/5-ethynyl-2'-deoxyuridine labeling, radioisotope tracing, CRISPR gene editing, and analysis of signaling gene sets in human cancer tissues and xenograft models were performed to define the mechanisms underlying ESCC GFIP.
Glucose promotes growth factor-independent DNA replication and accumulation of PEP in ESCC cells. PEP is the direct phospho-donor to poHis58-FAK within a known "HG" motif for histidine phosphorylation. Glucose-induced poHis58 promotes growth factor-independent FAK-mediated proliferation. Furthermore, glucose activates phosphatidylinositol-3'-kinase/AKT via poHis58-FAK signaling. Non-phosphorylatable His58A-FAK reduces xenograft growth.
Glucose induces ESCC, but not esophageal adenocarcinoma GFIP via PEP-His58-FAK-AKT signaling. ESCC progression is controlled by actionable growth factor-independent, glucose-induced pathways that regulate proliferation through novel histidine phosphorylation of FAK.
大多数针对癌症的靶向治疗旨在阻断生长因子刺激的致癌生长。然而,响应率低,对治疗的耐药性高。一种机制可能与肿瘤细胞诱导生长因子非依赖性增殖(GFIP)的能力有关。本项目旨在了解以下两种情况:(1)癌细胞如何通过利用葡萄糖的关键代谢产物,如磷酸烯醇丙酮酸(PEP),优先获得主要的生长优势,从而驱动增殖;(2)食管鳞状细胞癌(ESCC)细胞而不是食管腺癌细胞,如何通过糖酵解激活磷酸组氨酸(poHis)介导的信号传导,通过粘着斑激酶(FAK)诱导 GFIP。
要测试的假设是,葡萄糖诱导的 ESCC GFIP 是由 PEP 介导的 FAK 组氨酸磷酸化(poHis)促进的,这使得 ESCC 进展可以通过阻断 poHis 信号来靶向。进行了包括溴脱氧尿苷/5-乙炔基-2'-脱氧尿苷标记、放射性同位素追踪、CRISPR 基因编辑以及人类癌症组织和异种移植模型中信号基因集分析在内的生化、分子生物学和体内实验,以确定 ESCC GFIP 的潜在机制。
葡萄糖促进 ESCC 细胞生长因子非依赖性 DNA 复制和 PEP 的积累。PEP 是已知组氨酸磷酸化“HG”基序中 poHis58-FAK 的直接磷酸供体。葡萄糖诱导的 poHis58 促进生长因子非依赖性 FAK 介导的增殖。此外,葡萄糖通过 poHis58-FAK 信号激活磷脂酰肌醇-3'-激酶/AKT。不可磷酸化的 His58A-FAK 减少异种移植物的生长。
葡萄糖通过 PEP-His58-FAK-AKT 信号诱导 ESCC,但不诱导食管腺癌 GFIP。ESCC 进展受可操作的生长因子非依赖性、葡萄糖诱导的途径控制,该途径通过 FAK 的新型组氨酸磷酸化调节增殖。